Mizuho Reiterates Outperform on WAVE Life Sciences, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has reiterated an Outperform rating on WAVE Life Sciences (NASDAQ:WVE) and maintained a price target of $19.
June 25, 2024 | 4:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mizuho analyst Salim Syed has reiterated an Outperform rating on WAVE Life Sciences and maintained a price target of $19.
The reiteration of an Outperform rating and the maintenance of a $19 price target by a reputable analyst can boost investor confidence in WAVE Life Sciences, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100